Newly Published Visiongain Report: Global Biosimilar Monoclonal Antibodies Forecast 2020-2030

Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab

Purchase the full report or download free sample pages: https://www.visiongain.com/report/global-biosimilar-monoclonal-antibodies-forecast-2020-2030/

The global biosimilar monoclonal antibodies market is expected to grow at a CAGR of 9.6% in the second half of the forecast period. The market is expected to grow at a CAGR of 23.8% from 2015-2027. The market is estimated at $4.2bn in 2020 and $7.9bn in 2027.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 204-page report you will receive 72 tables and 72 figures- all unavailable elsewhere.

The 204-page report provides clear detailed insight into the global biosimilar monoclonal antibodies market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

o Global Biosimilar Monoclonal Antibodies Market forecasts from 2017-2027

o Along with revenue prediction for the overall world market for biosimilar monoclonal antibodies, our investigation shows forecasts to 2027 for the market segmented by compound:
o Infliximab
o Rituximab
o Abciximab
o Trastuzumab
o Adalimumab
o Bevacizumab

o This report also shows revenue to 2027 for individual biosimilar mAb products in the market:
o Remsima/Inflectra
o Infimab
o Reditux
o BI695500
o CT-P10
o BI695501
o FKB327
o FKB238
o Mabtas
o AcellBia
o Maball
o Clotinab
o Abcixirel
o BCD-022
o BCD-021
o Herzuma
o CANMAB/Hertraz

o Our analyses show individual revenue forecasts to 2027 for these regional and national markets:
o The US Biosimilar mAb Market
o Japanese Biosimilar mAb Market
o EU5 Biosimilar mAb Markets
o BRIC and South Korea Biosimilar mAb Markets
o Rest of the World Biosimilar mAb Market

Global Biosimilar Monoclonal Antibodies Forecast 2020-2030

o This report profiles 10 leading companies either with biosimilar mAbs already on the market or in the pipeline

o Our study discusses strengths, weaknesses, opportunities and threats affecting the biosimilar monoclonal antibodies market

Visiongain's study is intended for anyone requiring commercial analyses for the biosimilars monoclonal antibodies market. You find data, trends and predictions.

Buy our report today Global Biosimilar Monoclonal Antibodies Forecast 2020-2030: Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab.

Related Reports:

Global Surgical Sutures Market 2020-2030: https://www.visiongain.com/report/global-surgical-sutures-market-2020-2030/

Medical Robotic Systems Market Report 2020-2030:
https://www.visiongain.com/report/medical-robotic-systems-market-report-2020-2030/

Medical Oxygen Concentrators Market Report 2020-2030: https://www.visiongain.com/report/medical-oxygen-concentrators-market-report-2020-2030/

For more Pharma reports, visit our website:
https://www.visiongain.com/industries/pharma/

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Visiongain Limited
Airport House
Purley Way
Surrey
London
CR0 0XZ
United Kingdom

About Visiongain:

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

This release was published on openPR.